Therapeutic vaccination in chronic hepatitis B virus carriers

Expert Review of Vaccines

Volumn 5, Issue 5, 2006, Pages 707-716

  Pol, Stanislas ^a   Michel, Marie Louise ^b  

^a Université Paris V René Descartes ^*  (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Chronic infection; Clinical trial; DNA vaccine; Hepatitis B; Immunotherapy; Vaccination

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALUMINUM HYDROXIDE; BIOHEP B; DNA VACCINE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; LAMIVUDINE; MEINYU; PEGINTERFERON; PHOSPHORYL LIPID A; PLASMID DNA; QS 21; RECOMBINANT HEPATITIS B VACCINE; TENOFOVIR; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ADJUVANT THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VIRUS CARRIER; VIRUS ENVELOPE; VIRUS NUCLEOCAPSID; VIRUS RECOMBINANT; VIRUS REPLICATION;

CLINICAL TRIALS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; LIPOPROTEINS; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 33845877461     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.5.707     Document Type: Review

References (70)

1. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 337(24), 1733-1745 (1997).
2. Peters M, Vierling J, Gershwin ME et al. Immunology and the liver. Hepatology 13(5), 977-994 (1991).
3. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119(1), 172-180 (2000).
4. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352(26), 2682-2695 (2005).
5. Aloman C, Wands JR. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? Hepatology 38(6), 1584-1587 (2003).
6. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125(2), 292-297 (2003).
7. Lebray P, Vallet-Pichard A, Michel ML et al. Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. J. Hepatol. 39 (Suppl. 1), S151-S159 (2003).
8. Chisari FV. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13, 29-60 (1995).
9. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5(3), 215-229 (2005). •• Assesses recent advances in our understanding of viral hepatitis, mechanisms of virus-host interaction in acute hepatitis B and C and immunological aspects of chronic hepatitis.
10. + T cells. This reinforces the therapeutic approach of inhibiting HBV by using antiviral drugs before using vaccines to boost HBV-specific immunity
11. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol. 74(5), 2255-2264 (2000).
12. Wieland SF, Guidotti, LG, Chisari FV. Intrahepatic induction of α/β interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol. 74(9), 4165-4173 (2000).
13. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl Acad. Sci. USA 101(17), 6669-6674 (2004).
14. Biermer M, Puro R, Schneider RJ. Tumor necrosis factor á inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-κB. J. Virol. 77(7), 4033-4042 (2003).
15. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J. Gen. Virol. 87(Pt 6), 1439-1449 (2006).
16. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 38(1), 4-13 (2003). • Highlights the role of the innate immune system in protecting the host from viral infection and discusses how early events after infection might influence the development of the adaptive immune response to HBV and hepatitis C virus infection.
17. Ikeda T, Lever AM, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 6(5), 962-965 (1986).
18. Jung MC, Hartmann B, Gerlach JT et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 261(2), 165-172 (1999).
19. Nouri-Aria KT, Arnold J, Davison F et al. Hepatic interferon-α gene transcripts and products in liver specimens from acute and chronic hepatitis B virus infection. Hepatology 13(6), 1029-1034 (1991).
20. Penna A, Del Prete G, Cavalli A et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 25(4), 1022-1027 (1997).
21. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. 97(7), 1655-1665 (1996).
22. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102(5), 968-975 (1998).
23. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39(4), 595-605 (2003).
24. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33(4), 963-971 (2001). •• Study showing that lamivudine treatment in chronic hepatitis B can restore cytotoxic T lymphocyte (CTL) reactivity. This effect may enhance the probability that T cell-based immune therapies delivered after antiviral treatment can successfully reconstitute a protective CTL response able to cure chronic HBV infection.
25. Lau GK, Suri D, Liang R et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122(3), 614-624 (2002).
26. Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J. Hepatol. 23(1), 98-101 (1995).
27. Rigopoulou EI, Suri D, Chokshi S et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 42(5), 1028-1036 (2005).
28. Pol S, Driss F, Michel M-L et al. Specific vaccine therapy in chronic hepatitis B infection. Lancet 344, 342 (1994).
29. Dikici B, Kalayci AG, Ozgenc F et al. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr. Infect. Dis. J. 22(4), 345-349 (2003).
30. Yalcin K, Acar M, Degertekin H. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31(4), 221-225 (2003).
31. Pol S, Nalpas B, Driss F et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 34(6), 917-921 (2001).
32. Couillin I, Pol S, Mancini M et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180(1), 15-26 (1999). • One of the first studies of vaccine therapy for chronic hepatitis B, showing that it was possible to reactivate envelope-specific T-helper cells after injection of conventional recombinant vaccine.
33. Ren F, Hino K, Yamaguchi Y et al. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J. Med. Virol. 71(3), 376-384 (2003).
34. + T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20(29-30), 3598-3612 (2002).
35. Safadi R, Israeli E, Papo O et al. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am. J. Gastroenterol. 98(11), 2505-2515 (2003).
36. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol. Today 21(11), 573-583 (2000).
37. + natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J. Immunol. 163(4), 2314-2321 (1999).
38. Celis E, Abraham KG, Miller RW. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 7(3), 563-568 (1987).
39. Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy [letter]. Lancet 345(8964), 1575-1576 (1995).
40. Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J. Med. Virol. 66(4), 452-460 (2002).
41. Horiike N, Fazle Akbar SM, Michitaka K et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J. Clin. Virol. 32(2), 156-161 (2005).
42. Vitiello A, Ishioka G, Grey HM et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95(1), 341-349 (1995).
43. Heathcote J, McHutchison J, Lee S et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30(2), 531-536 (1999).
44. Livingston BD, Crimi C, Grey H et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159(3), 1383-1392 (1997).
45. Livingston BD, Alexander J, Crimi C et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol. 162(5), 3088-3095 (1999).
46. Davis HL, Michel M-L, Whalen RG. DNA based immunization for hepatitis B induces continuous secretion of antigen and high levels of circulating antibody. Hum. Mol. Genet. 2, 1847-1851 (1993).
47. Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl Acad. Sci. USA 93(14), 7213-7218 (1996).
48. Sato Y, Roman M, Tighe H et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273(5273), 352-354 (1996).
49. Michel M-L, Davis HL, Schleef M et al. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl Acad. Sci. USA 92, 5307-5311 (1995).
50. Mancini M, Davis HL, Tiollais P, Michel ML. DNA-based immunization against the envelope proteins of the hepatitis B virus. J. Biotechnol. 44, 47-57 (1996).
51. Loirat D, Lemonnier FA, Michel ML. Multiepitopic HLA-A*0201- restricted immune response against hepatitis B surface antigen after DNA-based immunization. J. Immunol. 165(8), 4748-4755 (2000).
52. Mancini M, Hadchouel M, Davis HL et al. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc. Natl Acad. Sci. USA 93(22), 12496-12501 (1996). • Pioneer study of first demonstration of potential immunotherapeutic application of DNA-mediated immunization against an infectious disease.
53. Mancini M, Hadchouel M, Tiollais P, Michel ML. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-γ-secreting T cells after DNA-based immunization. J. Immunol. 161, 5564-5570 (1998).
54. Triyatni M, Jilbert AR, Qiao M, Miller DS, Burrell CJ. Protective efficacy of DNA vaccines against duck hepatitis B virus infection. J. Virol. 72(1), 84-94 (1998).
55. Rollier C, Sunyach C, Barraud L et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 116(3), 658-665 (1999).
56. Rollier C, Charollois C, Jamard C, Trepo C, Cova L. Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection. J. Virol. 74(10), 4908-4911 (2000).
57. Lu M, Hilken G, Kruppenbacher J et al. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J. Virol. 73(1), 281-289 (1999).
58. Prince AM, Whalen R, Brotman B. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 15(8), 916-919 (1997).
59. Pancholi P, Lee DH, Liu Q et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33(2), 448-454 (2001).
60. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55, 25-40 (2005).
61. Calarota SA, Leandersson AC, Bratt G et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J. Immunol. 163(4), 2330-2338 (1999).
62. Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351(9112), 1320-1325 (1998).
63. Tacket CO, Roy MJ, Widera G et al. Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17(22), 2826-2829 (1999).
64. Roy MJ, Wu MS, Barr LJ et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19(7-8), 764-778 (2001).
65. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21(31), 4604-4608 (2003).
66. Mancini-Bourgine M, Fontaine H, Scott-Algara D et al. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40(4), 874-882 (2004).
67. Yang SH, Lee CG, Park SH et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-ofconcept study. Gene Ther. 13(4), 1110-1117 (2006) (EPub ahead of print).
68. McConkey SJ. AASLD meeting. Hepatology 40, A1176 (2004).
69. Cooper CL, Davis HL, Morris ML et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24(6), 693-701 (2004).
70. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J. Immunol. 175(2), 633-639 (2005). • Provides a background of DNA vaccines including immunological mechanisms that play a role in their ability to generate immune responses. It also highlights the challenges encountered in the efforts to translate efficacy in preclinical models into clinical realities.